Dr. McGregor on Advances Made in the Adjuvant Setting of RCC | OncLive

Patient Communication About Adjuvant Therapy for RCC

Impact of Adjuvant Therapy on Treatment Selection in Advanced RCC | OncLive

Let’s use Keytruda (pembrolizumab) as an example… it is an FDA-approved immunotherapy drug used to treat several cancers, including melanoma, lung, bladder, head and neck, breast, and colorectal cancers. Average cost: around $11,000–$13,000 per dose (given every 3–6 weeks) It’s a PD-1 checkpoint inhibitor that blocks the PD-1 receptor on immune cells, releasing the immune “brakes” so T-cells can attack cancer cells that hide from detection. 🤷🏼‍♀️Common side effects: fatigue, nausea, rash, join